Avulsion is superior to argon plasma coagulation for treatment of visible residual neoplasia during EMR of colorectal polyps (with videos)
- PMID: 27080417
- DOI: 10.1016/j.gie.2016.03.1512
Avulsion is superior to argon plasma coagulation for treatment of visible residual neoplasia during EMR of colorectal polyps (with videos)
Abstract
Background and aims: EMR is used widely for treatment of nonpedunculated colorectal adenomas ≥ 2 cm. Recurrence at the resection site occurs in 10% to 30% of cases.
Methods: Records of consecutive patients referred for endoscopic resection over a 4-year period were reviewed retrospectively. In the first part of the study period, our routine practice was to use argon plasma coagulation (APC) to treat all visible residual neoplasia after exhaustive attempts at snare resection during EMR. In the second part of the study period, we changed our practice to use avulsion to treat all visible residual neoplasia after exhaustive attempts at snare resection during EMR. We analyzed the effect of this change in practice on recurrence rates after EMR.
Results: Two hundred twenty-three resected lesions were analyzed. Fifty-nine (26%) were treated with en-bloc EMR, 55 (25%) by piecemeal EMR with complete snare removal of all visible neoplasia, 63 (28%) by piecemeal EMR with APC of visible residual neoplasia, and 46 (21%) by piecemeal EMR with avulsion of visible residual neoplasia. There was no significant difference in adverse event rates among the 4 groups. The recurrence rates on follow-up colonoscopy were 4.2%, 3.0%, 59.3%, and 10.3%, respectively. The recurrence rate for patients treated with avulsion was significantly lower than for those treated with APC (odds ratio, .079; P < .001). Multivariate analysis demonstrated that use of avulsion instead of APC was a significant predictor of no recurrence.
Conclusions: After exhaustive attempts at snare resection during EMR, avulsion is superior to APC for treatment of residual visible neoplasia. Compared with APC, avulsion significantly decreases the recurrence rate without significantly increasing the risk of the procedure.
Published by Elsevier Inc.
Comment in
-
Residual visible neoplasia: approaches to overt and occult polyp fragments.Gastrointest Endosc. 2016 Nov;84(5):830-832. doi: 10.1016/j.gie.2016.09.003. Gastrointest Endosc. 2016. PMID: 27742044 No abstract available.
-
Avulsion for the treatment of visible residual neoplasia during EMR of colorectal polyps: Is "heat" required?Gastrointest Endosc. 2017 Jul;86(1):250-251. doi: 10.1016/j.gie.2017.02.020. Gastrointest Endosc. 2017. PMID: 28610864 No abstract available.
-
Response.Gastrointest Endosc. 2017 Jul;86(1):251-252. doi: 10.1016/j.gie.2017.03.025. Gastrointest Endosc. 2017. PMID: 28610865 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
